Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31012850 | 0.82 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL16370866 | 0.79 | CYP2C19 (0.39) | PTPN1 | |
| SCHEMBL785938 | 0.76 | POLB (0.33) | — | |
| SCHEMBL16460776 | 0.76 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL9981990 | 0.72 | METAP2 (0.30) | — | |
| SCHEMBL20535917 | 0.72 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL20535913 | 0.72 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL19965585 | 0.71 | POLB (0.31) | — | |
| SCHEMBL22578076 | 0.70 | — | — | |
| SCHEMBL10257396 | 0.69 | CYP1A2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987577-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987577-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | PTPN1 3178/4885FFAR3 392/4885 |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | PTPN1 3178/4885FFAR3 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.